Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo

Applied Microbiology and Biotechnology

Volumn 98, Issue 9, 2014, Pages 4053-4061

  Ye, Li ^a   Fan, Jiajun ^a   Shi, Xunlong ^a   Tao, Qun ^b   Ye, Dan ^b   Xian, Zongshu ^a   Zeng, Xian ^a   Li, Yubin ^a   Feng, Meiqing ^a   Ju, Dianwen ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai GenePharma Co Ltd   (China)

Author keywords

Biotherapy; Cytokine; Fusion protein; Immunotherapy; Interleukin 2; Monoclonal antibody; Tumor necrosis therapy

Indexed keywords

ENZYME ACTIVITY; MAMMALS; MONOCLONAL ANTIBODIES; PROTEINS; TOXICITY;

BIOTHERAPY; CYTOKINES; FUSION PROTEINS; IMMUNOTHERAPY; INTERLEUKIN-2; TUMOR NECROSIS;

TUMORS;

CYCLOPHOSPHAMIDE; HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; IL2 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SIZE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERSTITIAL PNEUMONIA; LONG TERM CARE; LUNG CANCER; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOUSE; NONHUMAN; ORGAN SIZE; ORGAN WEIGHT; PHARMACOKINETICS; RADIOACTIVITY; SINGLE DRUG DOSE; TUMOR NECROSIS; TUMOR REGRESSION; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

MACACA FASCICULARIS; MURINAE; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; INTERLEUKIN-2; LUNG NEOPLASMS; MELANOMA; MICE; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899971375     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-013-5349-0     Document Type: Article

References (37)

1. Atkins MB (2006) Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12:2353-2358
2. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM, Eastern Cooperative Oncology Group (2008) Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 26:5748-5754
3. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES (1999) Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 96:3957-3962
4. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N Y) 10:169-175
5. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99:1659-1665 (Pubitemid 34533039)
6. Chapman PB (2008) Combining a peptide vaccine with high-dose interleukin-2. J Clin Oncol 26:2250-2251
7. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW (2005) Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 23:1538-1547
8. Epstein AL, Chen FM, Taylor CR (1988) A novel method for the detection of necrotic lesions in human cancers. Cancer Res 48:5842-5848
9. Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP (2007) Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 13:2115-2120 (Pubitemid 46649880)
10. Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, Lo KM (2011) A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 17:3673-3685
11. Goldman B, DeFrancesco L (2009) The cancer vaccine roller coaster. Nat Biotechnol 27:129-139
12. Hoogenboom HR, Winter G (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germlineVH gene segments rearranged in vitro. J Mol Biol 227:381-388
13. Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, Yun A, Taylor CR, Epstein AL (1998) A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 13:255-268 (Pubitemid 28484005)
14. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL (1996) A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 56:4998-5004 (Pubitemid 26374441)
15. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL (2003) Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood 101:4853-4861 (Pubitemid 36857747)
16. Khawli LA, Hu P, Epstein AL (2005) NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res 11:3084-3093 (Pubitemid 40525215)
17. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ (2008) Next generation of immunotherapy for melanoma. J Clin Oncol 26:3445-3455
18. Li J, Hu P, Khawli LA, Epstein AL (2003) Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25+ T-cell depletion. Cancer Res 63:8384-8392 (Pubitemid 37549493)
19. Liu A, Hu P, Khawli LA, Epstein AL (2006) B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother 29:425-435 (Pubitemid 44288955)
20. Lode HN, Reisfeld RA (2000) Targeted cytokines for cancer immunotherapy. Immunol Res 21:279-288
21. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134:157-166 (Pubitemid 15191491)
22. Mårlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14:6515-6524
23. McDermott DF (2007) Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 13:716-720
24. Penichet ML, Morrison SL (2001) Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248:91-101 (Pubitemid 32167027)
25. Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J (2011) Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology 133:206-220
26. Rosenberg SA (2000) Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 6:S2-S7
27. Sasso EH, Silverman GJ, Mannik M (1991) Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol 147:1877-1883
28. Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER (2009) Tumori-nduced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res 69:2026-2033
29. Sharifi J, Khawli LA, Hu P, King S, Epstein AL (2001) Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics 20:305-312 (Pubitemid 34756999)
30. Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A, Viti F, Neri D (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5:2340-2350 (Pubitemid 40835403)
31. Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS (2008) Three phase II cytokine working group trials of gp100 (210 M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 26:2292-2298
32. van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, ExleyMA (2007) Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 13:2100-2108 (Pubitemid 46649878)
33. Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A (2008) The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 14:4951-4960
34. + T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67:7487-7494
35. Wei S, Shreiner AB, Takeshita N, Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE (2008) Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res 68:5432-5438
36. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm 21:5-14
37. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, Morrison SL (1994) The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 73:794-799 (Pubitemid 24046633)